Mucocutaneous Epithelial Cell Growth Factor class drugs

1 result
  • kepivance

    (palifermin)
    Swedish Orphan Biovitrum AB (publ)
    Kepivance is indicated to reduce the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic therapy with autologous stem cell support. It serves as supportive care for preparative regimens likely to cause ≥ WHO Grade 3 mucositis.